  Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) are indicated for restoring normoglycemia in patients with type 2 diabetes ( T2D). This review analyzed and compared the efficacy results from 30 trials with the once-weekly ( OW) GLP-1 RAs albiglutide , dulaglutide , exenatide extended-release ( ER) and semaglutide. The 4 OW GLP-1 RAs showed a higher reduction in glycated hemoglobin ( HbA1c) , fasting plasma glucose ( FPG) and body<symptom> weight , when compared to placebo. Semaglutide significantly reduced the HbA1c level ( estimated treatment difference ( ETD): -0.62 %; 95 % confidence interval ( CI) , -0.79 to -0.44; P < 0.0001) , FPG ( ETD: -15 mmol/L; 95 % CI , -22 to -8.3; P < 0.0001) and body<symptom> weight ( ETD: -3.73 kg; 95 % CI , -4.53 to -2.93; P < 0.0001) compared with exenatide ER. A direct comparison between OW , once-daily ( OD) , and twice-daily ( BD) GLP-1 RAs indicated some trends in efficacy , for example , with OD liraglutide , providing a significant reduction in body<symptom> weight vs albiglutide ( ETD: 1.55 kg; 95 % CI , 1.05-2.06; P < 0.0001 for albiglutide) , dulaglutide ( ETD: 0.71 kg; 95 % CI , 0.17 -1.26; P = 0.011 for dulaglutide) , and exenatide ER ( ETD: 0.90 kg; 95 % CI , 0.39- 1.40; P = 0.0005 for exenatide ER). OW GLP-1 RAs also offered improved glycemic control when compared with the dipeptidyl peptidase-4 inhibitor sitagliptin. In conclusion , OW GLP-1 RAs offer a valid therapeutic option for T2D.